The Cimatron product line includes the CimatronE and GibbsCAM brands with solutions for mold design, die design, electrode design, 2.5 to 5 Axis milling, wire EDM, turn, Mill-turn, rotary milling, multi-task machining, and tombstone machining. Cimatron's subsidiaries and extensive distribution network serve and support customers in the automotive, aerospace, medical, consumer plastics, electronics, and other industries in over 40 countries worldwide.
Cimatron's shares are publicly traded on the NASDAQ exchange under the symbol CIMT. For more information, please visit Cimatron's web site at: http://www.cimatron.com
Safe Harbor Statement
This press release includes forward looking statements, within the meaning of the Private Securities Litigation Reform Act of 1995, which are subject to risk and uncertainties that could cause actual results to differ materially from those anticipated. Such statements may relate to Cimatron's plans, objectives and expected financial and operating results. The words "may," "could," "would," "will," "believe," "anticipate," "estimate," "expect," "intend," "plan," and similar expressions or variations thereof are intended to identify forward-looking statements. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, many of which are beyond Cimatron's ability to control. The risks and uncertainties that may affect forward looking statements include, but are not limited to: currency fluctuations, global economic and political conditions, marketing demand for Cimatron products and services, long sales cycles, new product development, assimilating future acquisitions, maintaining relationships with customers and partners, and increased competition. For more details about the risks and uncertainties related to Cimatron's business, refer to Cimatron's filings with the Securities and Exchange Commission. Cimatron cannot assess the impact of or the extent to which any single factor or risk, or combination of them, may cause. Cimatron undertakes no obligation to publicly update or revise any forward looking statements, whether as a result of new information, future events or otherwise.
CIMATRON LIMITED CONSOLIDATED STATEMENTS OF INCOME (US Dollars in thousands, except for per share data) Three months ended Twelve months ended ------------------ ------------------- December 31, December 31, 2010 2009 2010 2009 ------- ------- ------- -------- Total revenue 11,013 9,762 36,074 32,957 Total cost of revenue 1,634 1,719 5,876 6,186 ------- ------- ------- -------- Gross profit 9,379 8,043 30,198 26,771 Research and development expenses, net 1,692 1,347 6,014 5,736 Selling, general and administrative expenses 6,282 5,923 22,053 21,992 ------- ------- ------- -------- Operating income (loss) 1,405 773 2,131 (957) Financial income, net 43 38 97 19 Taxes on income (401) 639 (657) 949 Other 1 (41) (6) (41) ------- ------- ------- -------- Net income (loss) 1,048 1,409 1,565 (30) Less: Net (income) loss attributable to the noncontrolling interest 45 (18) 26 44 ------- ------- ------- -------- Net income attributable to Cimatron's shareholders $ 1,093 $ 1,391 $ 1,591 $ 14 ======== ======== ======== ======== Net income per share - basic and diluted $ 0.12 $ 0.15 $ 0.18 $ 0.00 ======== ======== ======== ======== Weighted average number of shares outstanding Basic EPS (in thousands) 8,959 9,128 9,000 9,156 ======== ======== ======== ======== Diluted EPS (in thousands) 8,983 9,128 9,000 9,156 ======== ======== ======== ======== CIMATRON LIMITED RECONCILIATION BETWEEN GAAP AND NON-GAAP INFORMATION (US Dollars in thousands, except for per share data) Three months ended December 31, 2010 2009 GAAP Adj. NON-GAAP GAAP Adj. NON-GAAP Total revenue 11,013 - 11,013 9,762 - 9,762 Total cost of revenue (1) 1,634 (147) 1,487 1,719 (147) 1,572 ------ ----- ------ ------ ----- ----- Gross profit 9,379 147 9,526 8,043 147 8,190 Research and development expenses, net 1,692 - 1,692 1,347 - 1,347 Selling, general and administrative expenses (1) 6,282 (99) 6,183 5,923 (100) 5,823 ------ ----- ------ ------ ----- ----- Operating income (loss) 1,405 246 1,651 773 247 1,020 Financial income, net 43 - 43 38 - 38 Taxes on income (2) (401) 221 (180) 639 (726) (87) Other (3) 1 - 1 (41) 43 2 ------ ----- ------ ------ ----- ----- Net income (loss) 1,048 467 1,515 1,409 (436) 973 Less: Net (income) loss attributable to the noncontrolling interest 45 - 45 (18) - (18) ------ ----- ------ ------ ----- ----- Net income attributable to Cimatron's shareholders $ 1,093 $ 467 $ 1,560 $ 1,391 $ (436) $ 955 ======= ====== ======== ======= ======= ====== Net income per share - basic and diluted $ 0.12 $ 0.17 $ 0.15 $ 0.10 ======= ======== ======= ====== Weighted average number of shares outstanding Basic EPS (in thousands) 8,959 8,959 9,128 9,128 ======= ======== ======= ====== Diluted EPS (in thousands) 8,983 8,983 9,128 9,128 ======= ======== ======= ====== (1) Non-GAAP adjustment to exclude non-cash amortization of acquired intangible assets. (2) Non-GAAP adjustment to exclude the effect of deferred taxes. (3) Non-GAAP adjustment to exclude loss from discontinued operations. (table continued) CIMATRON LIMITED RECONCILIATION BETWEEN GAAP AND NON-GAAP INFORMATION (US Dollars in thousands, except for per share data) Twelve months ended December 31, 2010 2009 GAAP Adj. NON-GAAP GAAP Adj. NON-GAAP Total revenue 36,074 - 36,074 32,957 - 32,957 Total cost of revenue (1) 5,876 (588) 5,288 6,186 (588) 5,598 ------- ----- ------ ------- ----- ----- Gross profit 30,198 588 30,786 26,771 588 27,359 Research and development expenses, net 6,014 - 6,014 5,736 - 5,736 Selling, general and administrative expenses (1) 22,053 (396) 21,657 21,992 (400) 21,592 ------- ----- ------ ------- ----- ----- Operating income (loss) 2,131 984 3,115 (957) 988 31 Financial income, net 97 - 97 19 - 19 Taxes on income (2) (657) 347 (310) 949 (999) (50) Other (3) (6) - (6) (41) 43 2 ------- ----- ------ ------- ----- ----- Net income (loss) 1,565 1,331 2,896 (30) 32 2 Less: Net (income) loss attributable to the noncontrolling interest 26 - 26 44 - 44 ------- ----- ------ ------- ----- ----- Net income attributable to Cimatron's shareholders $ 1,591 $ 1,331 $ 2,922 $ 14 $ 32 $ 46 ======= ====== ======== ====== ===== ===== Net income per share - basic and diluted $ 0.18 $ 0.32 $ 0.00 $ 0.01 ======= ====== ======== ====== ===== ===== Weighted average number of shares outstanding Basic EPS (in thousands) 9,000 9,000 9,156 9,156 ======= ====== ====== ===== Diluted EPS (in thousands) 9,000 9,000 9,156 9,156 ======= ====== ====== ===== (1) Non-GAAP adjustment to exclude non-cash amortization of acquired intangible assets. (2) Non-GAAP adjustment to exclude the effect of deferred taxes. (3) Non-GAAP adjustment to exclude loss from discontinued operations. CIMATRON LIMITED CONSOLIDATED BALANCE SHEETS (US Dollars in thousands) December 31, December 31, ------------ ------------ 2010 2009 ============ ========== ASSETS CURRENT ASSETS: Total cash, cash equivalents and short-term investments $ 10,221 $ 6,684 Trade receivables 5,708 5,422 Other current assets 2,275 3,308 ------- ------- Total current assets 18,204 15,414 ------- ------- Deposits with insurance companies and severance pay fund 3,279 2,935 ------- ------- Net property and equipment 949 1,046 ------- ------- Total other assets 12,469 13,285 ------- ------- Total assets $ 34,901 $ 32,680 ======== ========= LIABILITIES AND SHAREHOLDERS' EQUITY CURRENT LIABILITIES: Short-term bank credit $ 99 $ 456 Trade payables 1,685 1,064 Accrued expenses and other liabilities 8,260 6,991 Deferred revenues 2,275 2,397 ------- ------- Total current liabilities 12,319 10,908 ------- ------- LONG-TERM LIABILITIES: Accrued severance pay 4,297 4,104 Long-term loan 98 204 Deferred tax liability 1,002 1,365 ------- ------- Total long-term liabilities 5,397 5,673 ------- ------- Total shareholders' equity 17,185 16,099 ------- ------- Total liabilities and shareholders' equity $ 34,901 $ 32,680 ======== ======== CIMATRON LIMITED STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY (US Dollars in thousands) Accumulated Additional other Noncontrolling Share paid-in comprehensive Interest capital capital income (loss) Balance at December 31, 2009 $ (48) $ 304 $ 18,204 $ 75 ======= ====== ======== ===== Changes during the twelve months ended Deptember 31, 2010: Net income (loss) (26) Exercise of share options - 11 Unrealized loss on derivative instruments (79) Other 207 Stock option compensation 60 Investment in treasury stock Foreign currency translation adjustment (468) ------- -------- --------- ---------- Total comprehensive income Balance at December 31, 2010 $ (74) $ 304 $ 18,275 $ (265) (table continued) CIMATRON LIMITED STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY (US Dollars in thousands) Retained Earnings Total (accumulated Treasury Comprehensive shareholders' deficit) stock income (loss) equity Balance at December 31, 2009 $ (1,894) $ (542) $ 16,099 ========== ======= ========= Changes during the twelve months ended Deptember 31, 2010: Net income (loss) 1,591 1,565 1,565 Exercise of share options 11 Unrealized loss on derivative instruments (79) (79) Other 207 207 Stock option compensation 60 Investment in treasury stock (210) (210) Foreign currency translation adjustment (468) (468) -------- ------- --------- ------- Total 1,225 ========= comprehensive income Balance at December 31, 2010 $ (303) $ (752) $ 17,185 CIMATRON LIMITED STATEMENTS OF CASH FLOWS (US Dollars in thousands) Twelve months ended December 31, ------------- 2010 2009 Cash flows from operating activities: Net income (loss) $ 1,565 $ (30) Adjustments to reconcile net income (loss) to net cash provided by operating activities: Depreciation and amortization 1,512 1,575 Increase in accrued severance pay 228 138 Gain from sale of property and equipment, net 8 - Stock option compensation 60 73 Loss on disposal of businesses - discontinued operations - 43 Deferred taxes, net 406 (984) Changes in assets and liabilities: Decrease (increase) in accounts receivable and prepaid expenses (583) 1,854 Decrease (increase) in inventory 13 (15) Increase in deposits with insurance companies and severance pay fund (344) (216) Increase (decrease) in trade payables, accrued expenses and other liabilities 1,908 (1,164) ------ ------ Net cash provided by operating activities 4,773 1,274 ------ ------ Cash flows from investing activities: Purchase of property and equipment (384) (262) Cash and cash equivalents disposed of discontinued operations - (46) ------ ------ Net cash used in investing activities (384) (308) ------ ------ Cash flows from financing activities: Short-term bank credit (340) 301 Long-term bank credit (98) (104) Proceeds from issuance of shares upon exercise of options 11 - Investment in treasury stock (210) (153) ----- ----- Net cash used in (provide by) financing activities (637) 44 ----- ----- Net increase in cash and cash equivalents 3,752 1,010 Effect of exchange rate changes on cash (215) (53) Cash and cash equivalents at beginning of period 6,684 5,727 ------ ------ Cash and cash equivalents at end of period $ 10,221 $ 6,684 ========= ======== Appendix A - Non-cash transactions Purchase of property on credit $ 68 $ 10 ========= ========= Contact: Ilan Erez, Chief Financial Officer Cimatron Ltd. Tel.; +972-73-237-0114 E-mail: ilane@cimatron.com